Regeneron Pharmaceuticals (STU:RGO) Float Percentage Of Total Shares Outstanding: 94.62% (As of Jul. 11, 2026)


STU:RGO Regeneron Pharmaceuticals Inc STU:RGO
82 GF Score
Price €579.70
GF Value €787.99
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Regeneron Pharmaceuticals STU:RGO -0.67% 82 Float Percentage Of Total Shares Outstanding is 94.62% as of Jul. 11, 2026. GuruFocus rates STU:RGO with a GF Score™ of 82/100 and a GF Value™ of €787.99 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Regeneron Pharmaceuticals's float shares is 99.20 Mil. Regeneron Pharmaceuticals's total shares outstanding is 104.84 Mil. Regeneron Pharmaceuticals's float percentage of total shares outstanding is 94.62%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Regeneron Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Regeneron Pharmaceuticals's Institutional Ownership is 65.28%.

STU:RGO
82GF Score
Regeneron Pharmaceuticals Inc STU:RGO
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regeneron Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Regeneron Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=99.20/104.84
=94.62%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 94.62% mean?
Regeneron Pharmaceuticals (STU:RGO) has a Float Percentage Of Total Shares Outstanding of 94.62% as of Jul. 11, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Float Percentage Of Total Shares Outstanding too high?
Regeneron Pharmaceuticals' current Float Percentage Of Total Shares Outstanding is 94.62%. Overall, Regeneron Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Float Percentage Of Total Shares Outstanding compare to ALNY and RVMD?
Regeneron Pharmaceuticals' Float Percentage Of Total Shares Outstanding of 94.62% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Float Percentage Of Total Shares Outstanding is 94.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (STU:RGO) is currently considered Modestly Undervalued. The stock's GF Value™ is €787.99, compared to a current price of €579.70 — trading 26.4% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 94.62%. Regeneron Pharmaceuticals' overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Regeneron Pharmaceuticals (STU:RGO), the current Float Percentage Of Total Shares Outstanding is 94.62% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of €579.70 is trading 26.4% below its estimated GF Value™ of €787.99. GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for STU:RGO:

  • Float Percentage Of Total Shares Outstanding: 94.62%
  • GF Value™: €787.99 vs. price of €579.70 (26.4% below fair value)
  • GF Score™: 82/100 with 3 warning signs

No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
82GF Score

Get the complete analysis for STU:RGO

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€579.70
Price
€787.99
GF Value